To include your compound in the COVID-19 Resource Center, submit it here.

Targeting CDK in triple-negative breast cancer

A team at the University of California, San Francisco has found a dysregulated MYC pathway that underlies the majority of triple-negative breast cancers-a form of the disease with limited treatment options.1 The researchers also showed that inhibitors of cyclin dependent kinase, a target upon which MYC-upregulated cancers are dependent, could selectively kill the triple-negative cancer cells.

The group is planning a clinical trial of an undisclosed cyclin dependent kinase (CDK) inhibitor.

Triple-negative breast cancers do not express estrogen receptor, progesterone receptor and HER2 (EGFR2; ERBB2; neu). These tumors are thus insensitive to many of the treatments for other breast cancer subtypes, such as hormone ablation and Herceptin trastuzumab, a humanized anti-HER2 mAb marketed by Roche and its Genentech Inc. unit.

Due to the lack of well-defined targets, developing targeted therapies against triple-negative disease has

Read the full 1313 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers